2025 Annual Meeting | LS2 - Late-breaking Science 2

Date Tuesday 04/08/25

Time 05:45 PM - 07:15 PM PDT Add To Calendar

Location San Diego Convention Center | 6A

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Scientific Platform Session

Topic(s) General Neurology, Autoimmune Neurology, Child Neurology and Developmental Neurology, Movement Disorders, Multiple Sclerosis

CME Available 1.50 CME credits

Event Timeline
05:45 PM - 05:51 PM PDT	Speaker	Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results of a Phase 3 Study
05:51 PM - 05:57 PM PDT	Speaker	Phase 3 Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy Data in AChR+ Generalized MG Subpopulation Through Week-52
05:57 PM - 06:03 PM PDT	Speaker	Physiologic and Anatomical Evidence of Neuronal Repair and Remyelination from the Long-Term Open Label Extension of the Phase 2 VISIONARY-MS Trial
06:03 PM - 06:09 PM PDT	Speaker	ION859, Which Targets LRRK2 RNA to Reduce CNS LRRK2 Protein Production, is Well-tolerated and Potently Reduces CSF LRRK2 Protein and pRAB10 Levels in Parkinson’s Disease Patients
06:09 PM - 06:15 PM PDT	Speaker	TRANQUIL: Pivotal Study of the Felix NeuroAI Wristband in Patients with Essential Tremor
06:15 PM - 06:21 PM PDT	Speaker	MicroRNA Profiling and Iron-Related Modulation as Key Markers for Target Engagement in ALS Treatment with PrimeC
06:21 PM - 06:27 PM PDT	Speaker	RGX-202, an Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy: Interim Clinical Data
06:27 PM - 06:33 PM PDT	Speaker	Real-World Benefits and Tolerability of Trofinetide for the Treatment of Rett Syndrome: Interim Analysis of the LOTUS Study
06:33 PM - 06:39 PM PDT	Speaker	Leriglitazone Achieved a Primary Endpoint Based on Disease Arrest in Patients with Childhood Cerebral Adrenoleukodystrophy in the NEXUS Open-Label Phase 2/3 Study
06:39 PM - 07:15 PM PDT	Q&A	Poster Q&A

��ɫ��